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Introduction 
Emerging from the literature is a consistent 
observation that cognitive dysfunction, a 
transdiagnostic psycho- pathological domain in 
psychiatry, is a principal determinant of a person’s 
general function and other patient-reported  outcomes  
(PROs).1,2  During  the  past 
 
two decades, it has been amply documented that 
neuropsychiatric disorders (NPDs) disproportionately 
account for burden of illness attributable to chronic 
noncommunicable medical disorders globally.3 It is 
also likely that human capital costs attributable to 
NPDs will disproportionately increase as a 
consequence of popula- tion aging and beneficial risk 
factor modification of other common and chronic 
medical disorders (e.g., cardiovascular disease).4 The 
early age at onset, the relatively high incidence and 
prevalence, and the chronic and unfavorable illness 
trajectory, as well as the absence 
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of scalable, preventable, disease-modifying and/or 
cura- tive therapies for NPDs account for the 
staggering human, societal, and economic   costs.5,6 
The ignominious psychosocial and human capital 
consequences of NPDs have provided the impetus to 
identify the dimensions/domains of psychopathology 
that primarily mediate health outcomes among 
affected individuals. Whether NPDs are typologized 
according to severity (i.e., common, severe), age of 
onset of initial observable characteristics (i.e., 
childhood, adulthood, late life), and/or conceptual 
pathophysiological pro- cesses (i.e., 
neurodevelopmental, neurodegenerative), deficits in 
cognitive function account for more variance in 
PROs and costs attributable to NPDs than any other 
psychopathological  domain.1,2,7 
For example, major depressive disorder (MDD) 
debases human capital more than any other brain-
based disorder among younger populations (i.e., 18–
45 years).8 Epidemiological and clinical studies 
provide results that are in accordance with the 
assertion that cognitive deficits (self-rated, 
objectively measured) account for more variability in 
interpersonal adjustments and/or workplace 
performance (i.e., absenteeism, presenteeism) than 
total depression symptom severity and/or other 
domains (i.e., factors) in persons with mood disor- 
ders.9–12 It is additionally noted that cognitive 
deficits in MDD may predate the onset of “mood 
symptoms” in MDD and may progress in overall 
magnitude of deficits as a function of episode 
frequency/illness duration.13,14 
Notwithstanding the availability of multiple 
modalities of antidepressant treatment, relatively few 
studies in psychiatry have primarily sought to 
determine whether improving cognitive function in 
MDD improves PROs and/ or is cost effective.10,15 
The mediational relevance of cognition in MDD 
potentially extrapolates to all NPDs, indicating that 
screening for, measuring, preventing, and treating 
cognitive deficits in psychiatry is not only a primary 
therapeutic target, but also should be conceptua- lized 
as a transdiagnostic domain to be considered 
regardless of patient age and/or differential 
diagnosis.16,17 
 
Transdiagnostic  domains 
In keeping with the view that disturbances in 
cognitive functions are a transdiagnostic 
phenomenon, the National Institutes of Health has 
proffered the Research Domain Criteria (RDoC), 
which broadly aims to provide a biobehavioral 
mechanistic matrix of NPDs.18 Among 
NPDs, deficits in general cognitive function, 
social cognition (i.e., theory of mind), 
negative cognitive valence systems (e.g., 
perceived threat), and positive cognitive 
valence systems (e.g., motivation and 
reward) are distributed across four of the 
current five RDoC domains.19–21 The 
RDoC framework is supported by animal     
and    human     cognitive    neuroscience    
data 
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indicating that domain-based psychopathology (i.e., self-
report, observable characteristics) is subserved by discrete 
multilevel and multimodal substrates. It is expected that 
future discovery and development of psychiatric treatments 
are more likely to adopt a “domain-based” rather than a 
“disease-based” (e.g., bipolar   disorder,   schizophrenia)   
approach.22–24      For 
example, a treatment capable of ameliorating abnormal- ities 
in reward or cognition domain would not only have 
transdiagnostic application, but also would mimic the 
strategic framework of developing treatments in other chronic 
diseases (i.e., disease-agnostically targeting 
dimensions/domains). 
 
Importance of cognition as a transdiagnostic domain 
The relevance of cognitive domain disturbances as principal 
mediators of health outcomes across NPDs is expected to only 
amplify as the global economy and workforce adapt to the 
“human capital” or “digital” economy.25,26 Moreover, 
quality of care initiatives across multiple jurisdictions, as well 
as greater emphasis on cost effectiveness and containment, 
provide the impetus for the health-care ecosystem, and its 
stakeholders, to place greater emphasis on prevention, early 
interven- tion, risk factor modification, and specific targeting 
of critical determinants of health outcomes.27 Tacit to this 
reprioritization is the requirement for health-care providers to 
be familiar with a systematic approach to assessing cognitive 
functions as key determinants of proximal as well as distal 
health outcomes, agnostic of age and any preliminary 
differential diagnostic consid- erations. Hitherto, health-care 
providers have received extensive education in the approach 
to screening for (e.g., Mini Mental Status Exam [MMSE]) 
and diagnosing cognitive deficits in elderly populations.28 
Notwithstand- ing this, there has been relatively less attention 
(and consequently, deficiencies in best practices) given to a 
systematic screening/assessment of cognitive function deficits 
(i.e., subjective and/or objective) in pediatric and/or 
nongeriatric populations presenting to health- care providers, 
wherein cognitive disturbances are the primary focus of 
clinical attention. 
Against this background, we aim herein to provide health-
care providers with a meta-guideline for cognitive dysfunction 
(i.e., subjective, objective) in clinical prac- tice with an 
emphasis on screening and differential diagnosis. We 
purposefully avoid an approach to cogni- tive dysfunction that 
is disease specific and/or gives priority to age. Instead, we 
approach cognitive function as informed by cognitive 
neuroscience: cognition is a transdiagnostic domain that 
should be assessed system- atically regardless of differential 
diagnoses.29 It is recognized that cognitive dysfunctions vary 
across NPDs and individuals as well as within individuals as a 
function 
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FIGURE 1. Algorithm for cognitive screening and assessment in the clinical setting. 
of illness progression. It is also well established that 
multiple sociodemographic, clinical, and treatment 
factors moderate overall cognitive function as well as 
domain-specific performance. 
It is our view that approaching psychopathology 
with a domain/dimensional-based approach (i.e., 
rather than 
a disease-specific approach) reflects clinical practice 
and is not fundamentally different than the approach 
taken to other targets in chronic disease regardless of 
etiology or diagnosis (e.g., hypertension, peripheral 
blood glu- cose).30,31 It is anticipated  that  a 
systematic  approach to screening and measuring 
cognitive dysfunction across 
 
Expert Consensus on Screening and Assessment in Cognition in Psychiatry  
 
 
NPDs will streamline assessment, diagnosis, and care 
pathways, and it is hoped that this tactic will presage 
greater precision, consistency, appropriateness, and 
cost effectiveness of care. 
 
Systematic Approach to Assessing Cognition 
(Figure 1) For patients presenting with cognitive 
complaints as a focus of clinical concern or for whom 
cognitive deficits are suspected based on change in 
patient function, the initial step begins with 
ascertaining whether the cognitive deficits are 
subjective and/or objective. Across NPDs, it is well 
established that subjective  and  objective  cognitive  
complaints   exhibit 
minimal correlation.32–37  A separate body of    
literature 
indicates that changes in subjective and objective 
cognitive measures over time may correlate to a 
greater extent than pretreatment cross-sectional 
cognitive measures.38,39 
The dissociation between subjective and objective 
cognitive performance is a consequence of multiple 
moderating factors (e.g., depressive symptoms).40 
Impli- cit is the need for health-care practitioners to 
provide reassurance when cognitive deficits are solely 
subjective and are not verified objectively and/or 
associated with meaningful functional impairment. 
Notwithstanding this, vigilance for the possibility of 
objective cognitive impairment should remain in 
circumstances in which a patient or caregiver reports 
functional deficits in the absence of subjective 
cognitive complaints. 
Available evidence also indicates that informant 
(e.g., family) ratings of an identified patient’s 
cognitive function are reliable, valid, and highly 
correlated with both subjective and objective ratings 
of cognition. For example, the Cognitive Assessment 
Interview was derived from the Schizophrenia 
Cognition Rating Scale and the Clinical Global 
Impression of Cognition in Schizophrenia with 
neurocognitive battery measures, functional 
assessment, and functional outcome.41 
Sociodemographic information with a particular 
emphasis on age and education are essential, and 
these are two of the most replicated variables 
influencing general cognitive performance. Early 
childhood adversity (ECA) has been associated with a 
myriad of medical and/ or mental disorders. 
Preclinical evidence, as well as emerging evidence in 
human studies, indicates that ECA may be associated 
with abnormalities in general cogni- tive functions 
and social cognition. It is well established that ECA 
exerts deleterious effects on cognitive emo- tional 
processing that overlap with positive and 
negative valence disturbances.42 
As with all patient-reported chief 
complaints and/or objectively established 
deficits in psychosocial and/or workplace 
function, characterization of the onset, 
trajectory,    progression,    and    course    is   
warranted. 
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Determining whether the cognitive complaint/deficit is 
enduring or progressive has diagnostic implications (e.g., 
intellectual disability, bipolar disorder/major neu- rocognitive 
disorder, respectively). Moreover, cognitive 
complaints/objective deficits that temporally precede the 
overt onset of an NPD may represent heterotypic continuity, 
vulnerability markers, early prodrome of the NPD, or a 
distinct and separate disease process. Conversely, cognitive 
deficits may become a focus of clinical concern following the 
onset and/or amelioration of a discrete medical/mental 
disorder (e.g., traumatic brain injury, major depressive 
disorder) or spontaneous or medication-induced remission.43 
 
Subdomains of cognition 
Cognitive functions have been variably defined and 
operationalized. Delineating whether deficits in cogni- tion 
are primarily in the domains of learning and memory, 
attention/concentration, executive functions (e.g., planning, 
sequencing, organizing, impulse con- trol), processing speed, 
language, and/or social cogni- tion is critical.1 It is recognized 
that cognitive subdomains exhibit multilinearity, yet as 
discrete sub- domains often are subserved by discrete yet 
interrelated biological substrates. A separate yet overlapping 
taxon- omy is “hot” and “cold” cognition, referring to the 
presence and absence of emotional valence, respec- tively.44 
Examples of “hot” cognition include, but are not limited to, 
rumination, negative attentional biases, affect perception and 
recognition, and catastrophic reactions to real and/or 
perceived slights.45 
Deficits in any subdomain are not pathognomonic of any 
single NPD or medical disorder. The profile of cognitive 
deficits may provide insights into possible disease 
considerations. For example, childhood onset of persisting 
attentional disturbances with difficulties in impulse control 
are characteristic features of attention- deficit hyperactivity 
disorder, while deficits in memory (e.g., spatial) may suggest 
early prodromal stages of a major neurocognitive disorder 
when significant deficits in multiple domains of psychosocial 
functioning are present.46 
 
Functional consequences of alterations in cognitive 
performance 
The functional consequences of cognitive dysfunction are 
essential when attempting to establish clinical 
meaningfulness. To the extent possible, characterizing 
“premorbid” function is instructive, as many individuals with 
significant “cognitive reserve” may manifest sig- nificant 
subjective cognitive decline that may not be verifiable using 
norms whereby many cognitive screen- ing  and measuring 
tools have been validated.     General 
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psychosocial functioning, independence in everyday 
living, academic performance (where applicable), 
and workplace productivity/presenteeism should be 
evalu- ated. Among individuals who are working, 
presenteeism is essential information, as workplace 
productivity decreases are disproportionately 
accounted for by pre- senteeism than absenteeism.4 
A review of activities of daily living (ADLs) and 
instrumental ADLs (IADLs) should also be 
conducted. A host of medical disorders are highly 
associated with decreased cognitive performance in 
both younger and older populations. 
 
Medical illness and cognition 
It is well established that thyroid dysfunction is linked 
to cognitive impairment and should be corrected 
biochemi- cally.47 It has also emerged that impaired 
glucose tolerance, diabetes mellitus, and obesity are 
associated with impaired cognitive performance and 
mild cognitive impairment, as well as major cognitive 
disorders.48 Many other medical disorders with 
associated anticognitive effects should also be 
considered, including, but not limited to, delirium, 
cerebrovascular accidents, and traumatic brain injury. 
Finally, maladaptive behaviors impacting cognition, 
notably disruption in sleep dura- tion, efficiency, 
and/or reversal of day/night schedule should be ruled 
out as modifiable contributors of cognitive 
impairment.49 
 
Medication effects and cognition 
Health-care providers should also review prescription 
and over-the-counter (OTC) medications, as well as 
complementary alternative medicines (CAMs), that 
may be associated with anticognitive effects. For 
example, mechanistically dissimilar agents like 
benzodiazepines, antihistamines, anticonvulsants, 
and corticosteroids are all associated with 
anticognitive effects.50,51 The role of 
anticholinergics and, of more recent interest, 
histamine antagonism, needs to be carefully assessed. 
Many OTCs with sedating/somnolent effects may 
have anticognitive effects, and despite marketing 
claims, procognitive effects   associated   with   most   
CAMs   have   not  been 
established. The anticognitive effects of alcohol con- 
sumption are well known and need to be assessed on 
a personalized basis, as is the case for opiate use.52 
Moreover, the careful review of substance use is 
required, as multiple substances that are misused are 
highly associated with impaired cognitive functions 
(methamphetamines, ketamine).53,54 
The high and rising rates of cannabis use 
across jurisdictions, fueled in part by 
changing legal, cultural, social, and political 
factors, is resulting in a larger number of 
individuals reporting cannabis  consumption 
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during the past year.55 Cannabis (notably Tetrahydro- 
cannabinol (THC)), is established as anticognitive in both 
healthy and clinical populations, with the extent of 
reversibility variably reported.56 In addition to antic- ognitive 
effects, phytocannabinoids like THC are also associated with 
amotivation and incident mental dis- orders (e.g., 
schizophrenia), which are also associated with cognitive 
impairment.57 Circumstances in which cognitive deficits 
persist, despite ruling out and/or managing any of the 
foregoing secondary causes, invite the need for additional 
screening for cognitive function as required. A further issue 
for consideration is the reporting of null findings in studies of 
approved antidepressant medication and its effects on 
cognition. As has been pointed out, clear evidence of a lack of 
positive effects should be considered in the context of the 
selected measures’ capacity to demonstrate assay 
sensitivity.58 
 
Tools for measuring cognition 
Multiple screening, diagnostic, and measurement tools for 
cognitive functions are available and/or published in the 
biomedical literature. Available instruments vary in their 
administration (e.g., patient-administered), inter- face (e.g., 
digital), duration, subjective and/or objective measurements, 
domains evaluated, proprietary and copyright properties, 
requirement for expert interpreta- tion, scalability and 
appropriateness for point-of-care utilization, psychometric 
properties, validation proce- dures, and 
cultural/regional/country sensitivity. No single tool stands out 
as the gold standard akin to the sphygmomanometer for blood 
pressure evaluation. Notwithstanding, guiding principles in 
selecting a screening tool for cognitive dysfunction include 
that it  is patient-administered, brief, digital and interoperable 
with other digital platforms, available at point-of-care, and 
free of cost; integrates both subjective and objective cognitive 
performance; has appropriate psychometric properties;     and     
provides     actionable    information 
immediately.59,60 
A recently validated short and feasible tool for assessment 
of cognition in psychotic and depressive disorders is the SCIP 
(Screen for Cognitive Impairment in Psychiatry).61 The SCIP 
is a brief cognitive screening tool consisting of five short 
objective tests of cognition that can be administered in 10–15 
minutes quantifies difficulties with verbal working memory, 
verbal learning and memory, verbal fluency, and psychomotor 
speed and has high decision validity in patients with mood 
disorders (i.e., high sensitivity and specificity for cognitive 
impairment). 
Another  tool is the THINC-it tool. The THINC-it tool  is 
free of charge, digitalized, patient  administered,   and 
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has been validated as a screening  tool  in  adults  with 
Major Depressive Disorder (https://thinc.progress.im/). 
The THINC-it tool can be used at point of care and 
provides the end user with an easy to translate 
assessment and can be used as a repeat measure 
across time, in adults with Major Depressive 
Disorder. The MMSE and the MOCA are well-
known tools  for  dementia   screening,62–64   and   
their   use,   along   with 
establishment of functional impairment in ADLs and 
IADLs, can be valuable when a possible major 
cognitive disorder is suspected. However, the MMSE 
and MOCA may not be sufficient to identify 
cognitive dysfunction in older populations with 
higher cognitive baseline or younger populations 
with diagnoses that have cognitive impairment as one 
of many possible symptoms (e.g., bipolar disorder, 
schizophrenia, diabetes mellitus, hypothyroidism). A 
point to be emphasized is the importance of an age-
informed approach to the screen- ing tool selected for 
cognitive impairment (i.e., the MMSE/MOCA is 
suitable for older patients, but not younger 
patients).65 
Ongoing research endeavors to identify new 
techno- logical approaches in assessing cognitive 
dysfunction may provide more objective markers to 
supplement clinical assessment. Functional near-
infrared spectroscopy (fNIRS) is a noninvasive 
neuroimaging technology that maps the functions of 
the cerebral cortex by measuring hemodynamics.66 
Assessment of hemodynamics by fNIRS during 
cognitive tasks can be a promising biomarker in 
personalized psychiatric practice. 
If a major cognitive disorder is expected, appro- 
priate and thorough workup is encouraged (e.g., 
Alzheimer’s disease).67 If an individual exhibits 
deficits in two or more cognitive domains with no 
functional impairment, by definition, the individual 
has a mild cognitive disorder and should be 
prospectively evalu- ated for the possible declaration 
of major cognitive disorder. Subjective cognitive 
impairment with no objective    findings    and    no    
functional    impairment 
indicates that the individual has subjective cognitive 
complaints/age-related cognitive decline. 
Reassurance and follow-up are warranted. 
Multiple screening/measurement tools for 
cognitive function have been validated for specific 
and/or select mental/medical disorders.68 When 
major or mild cogni- tive disorder is not in the 
differential diagnosis, and age- related cognitive 
decline has been ruled out, it would not be 
unreasonable for cognitive functions to be measured 
with a tool with exceptional psychometric 
properties in healthy controls (age, sex, 
education-adjusted). It would be impossible 
to validate any tool across the plethora of 
medical conditions characterized by 
cognitive com- plaints. Indeed, preference is 
given to those screening tools validated in a 
specific disorder or disease state. The 
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widespread availability of mobile phones, health-related apps, 
and digital literacy provides a unique opportunity for 
screening and surveillance of cognitive function. However, 
relatively few digital solutions have a rigorous and controlled 
evidence-based approach supporting their validity as 
appropriate screening and monitoring tools for cognition in 
the general and medical population.69 
When screening provides evidence that cognitive 
impairment is present and impacting role functioning, steps 
can be taken to address ways  to  minimize, reverse, and adapt 
to the dysfunction. This starts with sharing the results of the 
screening and enlisting interpersonal and/or professional 
support needed to start  a treatment plan. 
 
Conclusion 
Cognitive dysfunction is a common complaint, a reason for 
high health-care utilization, a source of patient distress, and a 
principal determinant of health-care outcomes. It is also 
established that cognitive dysfunc- tion is a transdiagnostic 
abnormality with distinct and overlapping phenotypic 
characteristics across mental/ medical disorders. The 
foregoing provides the basis for health-care providers to 
prioritize cognitive dysfunction as a primary therapeutic 
target. As assessment and measurement have been 
demonstrated to improve health outcomes across chronic 
diseases, it is a testable hypothesis that screening and 
measuring cognitive dysfunction in the health-care ecosystem 
improves health outcomes among those affected. In the 
interim, adopting a systematic, coherent, and comprehensive 
approach to cognitive function evaluation that is prag- matic, 
patient-centric, comprehensive, and evidence- based is 
warranted. 
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